Dupilumab in Inflammatory Skin Diseases: A Systematic Review

Biomolecules. 2023 Mar 31;13(4):634. doi: 10.3390/biom13040634.


Dupilumab was first approved for the treatment of atopic dermatitis (AD) and blocks the signaling of interleukin (IL)-4 and -13. Several other chronic skin conditions share mechanistic overlaps with AD in their pathophysiology, i.e., are linked to type 2 inflammation. Most recently, dupilumab was approved by the U.S. Food and Drug Administration for prurigo nodularis (PN). Given its relatively good safety profile, effective off-label use of dupilumab has been reported for a multitude of dermatologic diseases and several clinical trials for dermatologic skin conditions are currently ongoing. We conducted a systematic review of applications of dupilumab in dermatology other than AD and PN by searching the databases PubMed/Medline, Scopus, Web of Science and Cochrane Library as well as the clinical trial registry ClinicalTrials.gov. We found several reports for effective treatment of bullous autoimmune diseases, eczema, prurigo, alopecia areata, chronic spontaneous urticaria, Netherton syndrome and a variety of other chronic inflammatory skin diseases.

Keywords: alopecia areata; atopic dermatitis; bullous pemphigoid; chronic spontaneous urticaria; contact dermatitis; dupilumab; eczema; prurigo nodularis; pruritus; review.

Publication types

  • Systematic Review
  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Dermatitis, Atopic* / drug therapy
  • Humans
  • Prurigo* / drug therapy
  • Skin


  • dupilumab
  • Antibodies, Monoclonal, Humanized

Grants and funding

This work was supported by the Clinician Scientist School Lübeck (CS01-2022), by the Cluster of Excellence Precision Medicine in Chronic Inflammation (DFG EXC 2167) and the Schleswig-Holstein Excellence-Chair Program from the State of Schleswig-Holstein.